Oppenheimer assumed coverage of Seres Therapeutics with an Outperform rating and $12 price target. There was no change to the firm’s estimates or price target, and Oppenheimer’s rating remains intact.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on MCRB:
- Seres Therapeutics, Nestle Health Science present late-breaking data on VOWST
- Seres Therapeutics call volume above normal and directionally bullish
- Seres Therapeutics price target lowered to $10 from $12 at Chardan
Questions or Comments about the article? Write to editor@tipranks.com